Previous studies have also shown that PEGylated-IFN-α therapy, which is the first-line choice of treatment for chronic hepatitis B, C, and D, induces weight loss and anorexia and indirectly increases the risk of TB reactivation, resulting in severe pulmonary TB [68–70]. The gene discussed is IFNA2; the disease is tuberculosis.